Sen. Grassley questions advocacy group funding

Share this article:

The ranking member of the Senate Finance Committee, Sen. Charles Grassley (R-IA) has asked state-level chapters of the National Alliance on Mental Illness (NAMI) to account for funds given directly to them by drug companies or coming to them through drug company funding of the organization.

An earlier inquiry of the national-level NAMI found that in 2005-2008, drug companies gave a total of $28.6 million to the organization, which has often been accused of being too supportive of mental health drugs and the companies that make them. “Public trust and public dollars are at stake,” Grassley said. “People rely on medical advice and taxpayers spend billions of dollars on prescription drugs and devices through Medicare and Medicaid. Public confidence could be greatly improved if financial relationships were disclosed. My legislative effort is a common-sense reform that would require the pharmaceutical and device industry to report money it gives to doctors.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?